Kinetics of Circulating Tumoral Cells in Bronchial Primitive Cancer
Overview
The pronostic value of Circulating Tumoral Cells(CTC) 's dosage by the method ISET® (tumoral cell isolation by size) in patients with bronchial cancer was previously demonstrated. However, no kinetic study was ever realized to study the value of the CTC as predictive indicator of answer to the therapy. This project plans to study patients in an early stage and patients at advance stage locally moved forward or metastatic of the disease by evaluation of the presence and the number of CTC before every cure. This collaborative and original study should allow to refine the diagnoses of answer and to plan the possible relapses what would allow a premature institution of the treatment.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Diagnostic
- Masking: None (Open Label)
- Study Primary Completion Date: November 30, 2018
Interventions
- Diagnostic Test: ISET® – Isolation by Size of Tumor cells
- early stage bronchial cancer patient will have a blood collection
- Diagnostic Test: ISET® – Isolation by Size of Tumor cells
- advanced stage bronchial cancer patient will have a blood collection
Arms, Groups and Cohorts
- Other: early stage bronchial cancer
- Early stage which can benefit from a surgical resection. A taking will be made in preoperative then in every consultation of follow-up after the intervention
- Other: advanced stage bronchial cancer
- Patients locally moved forward or at a metastatic stage handled by chemotherapy
Clinical Trial Outcome Measures
Primary Measures
- numeration of CTC (circulant tumoral cell)
- Time Frame: Day 1
Participating in This Clinical Trial
Inclusion Criteria
- patients with non-small cell lung cancer – accepting participation Exclusion Criteria:
- refusing participation
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Fondation Hôpital Saint-Joseph
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Jean P Tredaniel, Pr, Principal Investigator, Fondation Hôpital Saint-Joseph
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.